



For Immediate Release

April 5, 2007

Company Name: Dainippon Sumitomo Pharma Co., Ltd.

President: Kenjiro Miyatake

Stock Exchange Listings: Tokyo, Osaka, Nagoya

Security Code number: 4506

Investment in bio-venture fund

Dainippon Sumitomo Pharma Co., Ltd (Head Office in Osaka, President: Kenjiro Miyatake, hereafter DSP) has entered into an agreement to invest up to US\$30million (approximately JPY 3.6billion) into the “Apposite Healthcare Fund, L.P.”, a bio-venture fund.

DSP expects the investment will assist DSP in identifying new partnering opportunities with global life science venture companies which have novel technologies. These partnerships will provide new research ideas for novel NCEs, thereby improving DSP’s internal drug discovery capabilities and acting as a key part of its transformation into a leading international pharmaceutical company.

(Note) Fund Summary

Fund	:	Apposite Healthcare Fund, L.P.
Fund size	:	Over US\$200million
Term	:	Until March 2015, already started investment in April 2006
Investment	:	Life sciences, healthcare services
Geography	:	United States of America and European countries